However, the “redistribution lymphocytosis” caused by ibrutinib, which has led to the introduction of the CLL response category “partial response with lymphocytosis (PRL)”44, does not have any adverse long-term consequences even if prolonged, and these cells eventually die from the lack of microenvironmental pro-survival signals45. Here, PRL is linked to B-cell chronic lymphocytic leukemia.